I intend to and thank you for inviting me into the fold. My reasoning is simple - we are all aware of the current early stage trials being conducted on the in-house projects and know that these are likely to increase dramatically over the next 12 months. Most of the costs are non-recoverable from anyone else unless deals are done. The conducting of Phase 1, 2 and 3 trials can be a very costly exercise. The early Phase 1 and 2 trials can be conducted with a relatively small number of patients but as you get into Phase 3 trials with high patient numbers the costs will escalate hugely. When Lim was talking about having enough cash to cover two years worth of expenditure AT CURRENT BURN RATES I was quite surprised. I'd say that he was being economical with the truth! Anyway I think that if you ask anyone in the industry whether you could take a number of projects forward through Phase 3 trials for $35m pa you would be laughed at. When I asked Robert Uhl about this he said that HALO hadn't even completed their 2009 budgets yet so he couldn't comment.
Market Data 
Markets 
AI
